Akero Therapeutics Soars 10.07% on Analyst Upgrades, Investor Optimism

On March 28, 2025, Akero Therapeutics' stock surged by 10.07% in pre-market trading, indicating a significant bullish sentiment among investors.

Akero Therapeutics has seen a flurry of analyst activity, with Citi raising their price target to $80 and HC Wainwright increasing their target to $75, up from $72. These revisions reflect a growing optimism about the company's prospects, driven by positive developments in its pipeline and strategic initiatives.

Additionally, Proficio Capital Partners LLC has invested $320,000 in Akero Therapeutics, further bolstering investor confidence in the company's future growth potential. This investment, coupled with the recent analyst upgrades, suggests that Akero Therapeutics is poised for continued success in the biotech sector.